A critical review of model-based economic studies of depression: Modelling techniques, model structure and data sources

PharmacoEconomics

Volumn 30, Issue 6, 2012, Pages 461-482

  Afzali, Hossein Haji Ali ^a   Karnon, Jonathan ^a   Gray, Jodi ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antidepressants; Depression; Escitalopram; Modelling; Pharmacoeconomics; Serotonin uptake inhibitors; Venlafaxine.

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

CLINICAL FEATURE; DEPRESSION; ECONOMIC EVALUATION; ELECTROCONVULSIVE THERAPY; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MODEL; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RELAPSE; REVIEW; SIMULATION; SUICIDE; UNSPECIFIED SIDE EFFECT; VIRUS TYPING;

BIAS (EPIDEMIOLOGY); COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; DEPRESSIVE DISORDER, MAJOR; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; POLICY MAKING;

EID: 84861057537     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11590500-000000000-00000     Document Type: Review

References (122)

1. Paykal ES, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005; 15: 411-23 (Pubitemid 40943545)
2. Lecrubier Y. Is depression under-recognized and undertreated? Int Clin Psychopharmacol 1998; 13: S3-6
3. Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19-29 (Pubitemid 27171192)
4. World Health Organization. The world health report 2001: mental health - new understanding, new hope. Geneva:WHO, 2002
5. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262: 914-9 (Pubitemid 19208948)
6. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review ofthe literature. Diabetes Care 2000; 23: 934-42 (Pubitemid 30480020)
7. Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use: part 1 - depression and its treatment. Pharmacoeconomics 1997; 11 (5): 419-43 (Pubitemid 27240271)
8. Dunner DL, Kwong J, Houser t, et al. Improved healthrelated quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression. Prim Care Companion J Clin Psychiatry 2001; 3: 10-6 (Pubitemid 33807484)
9. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Canberra (ACT): Pharmaceutical Benefits Advisory Committee, 2008
10. Boxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27 (Pubitemid 27296586)
11. Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modelling practices: a suggested framework.Value Health 1998; 1: 131-47
12. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461-77 (Pubitemid 30398805)
13. Jones MT, Cockrum PC. A critical review of published economic modelling studies in depression. Pharmacoeconomics 2000; 17 (6): 555-83 (Pubitemid 30407881)
14. Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001; 15 (1): 59-83 (Pubitemid 32128491)
15. Iqbal SU, Prashker M. Pharmacoeconomic evaluation of antidepressants: a critical appraisal of methods. Pharmacoeconomics 2005; 23 (6): 595-606 (Pubitemid 40994127)
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: APA, 2000
17. Hirschfeld R. Clinical importance of long term antidepressant treatment. Br J Psychiatry 2001; 179: S4-8 (Pubitemid 32846115)
18. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52: 28-34
19. Nordstrom G, Despiegel N, Marteau F, et al. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J Med Econ 2010; 13: 516-26
20. Sado M, Knapp M, Yamauchi K, et al. Cost-effectiveness of combination therapy versus antidepressant therapy formanagement of depression in Japan. Aust N Z J Psychiatry 2009; 43: 539-47
21. Simon J, Pilling S, Burbeck R, et al. Treatment options in moderate and severe depression: decision analysissupporting a clinical guideline. Br J Psychiatry 2006; 189: 494-501 (Pubitemid 44876867)
22. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptakeinhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911-32 (Pubitemid 39612019)
23. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of costeffectivenessbetween the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91-107 (Pubitemid 37168799)
24. Lenox-Smith A, Greenstreet L, Burslem K, et al. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin Drug Investig 2009; 29 (3): 173-84
25. Trivedi MH, Wan GJ, Mallick R, et al. Cost and effectiveness of venlafaxine extended-release and SSRIs in theacute phase of outpatients treatment for major depressive disorder. J Clin Psychopharmacol 2004; 24: 497-506 (Pubitemid 39294705)
26. Armstrong EP, Skrepnek GH, Haim Erder M. Cost-utility comparison of escitalopram and sertraline in the treatmentof major depressive disorder. Curr Med Res Opin 2007; 23: 251-8 (Pubitemid 46333372)
27. Benedict A, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versus serotonin selective reuptakeinhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord 2010; 120: 94-104
28. Armstrong EP, Malone DC, Haim Erder M. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr Med Res Opin 2008; 24: 1115-21 (Pubitemid 351579169)
29. Wang PS, Patrick A, Azocar F, et al. The costs and benefits of enhanced depression care to employers. Arch Gen Psychiatry 2006; 63: 1345-53 (Pubitemid 44883167)
30. Aziz M, Mehringer AM, Mozurkewich E, et al. Cost-utility of two maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. Can J Psychiatry 2005; 50: 389-97 (Pubitemid 43161809)
31. Sobocki P, Ekman M, Ovanfors A, et al. The cost-utility of maintenance treatment with venlafaxine in patients withrecurrent major depressive disorder. Int J Clin Pract 2008; 62: 623-32 (Pubitemid 351348039)
32. Sobocki P, Ekman M, Agren H, et al. Model to assess the cost-effectiveness of new treatments for depression. Int JTechnol Assess Health Care 2006; 22: 469-77 (Pubitemid 44622967)
33. Fineberg HV. Decision trees: construction, uses, and limits. Bull Cancer 1980; 67: 395-404 (Pubitemid 11181444)
34. Lieu TA, Watson SE, Washington AE. The costeffectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynaecol 1994; 84: 903-12 (Pubitemid 24360245)
35. Fox-Rushby J, Cairns J. Economic evaluation. Maidenhead: Open University Press, 2009
36. Lam RW, Larsson Lonn S, Despiegel N. Escitalopram versus SNRIs as second line treatment. Int J Psychiatry Clin Pract 2009; 13: 35-6
37. GPRD Group. The general practice research database [online]. Available from URL: http://www.gprd.com [Accessed 2010 Aug 20]
38. Bielski RJ, Ventura D, Chang C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190-6
39. Montgomery SA, Huusom AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57-64 (Pubitemid 38721171)
40. Khan A, Bose A, Alexopoulos CG, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007; 27 (7): 481-92 (Pubitemid 46919700)
41. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopramversus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23: 1605-14 (Pubitemid 47122170)
42. Sobocki P, Ekman M, Agren H, et al. The mission is remission: health economic consequences of achieving fullremission with antidepressant treatment for depression. Int J Clin Pract 2006; 791-8 (Pubitemid 43881154)
43. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York (NY): Oxford UniversityPress, 1996
44. Agency for Healthcare Research and Quality. Medical expenditure panel survey [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data- stats/data-overview.jsp [Accessed 2010 Jun 20]
45. National Collaborating Centre for Mental Health. Management of depression in primary and secondary care [commissioned by NICE; national clinical practice guideline no. 23]. London: National Collaborating Centre for Mental Health, 2004
46. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord 1986; 10: 67-75 (Pubitemid 16109827)
47. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressantresistant chronic depression. Arch Gen Psychiatry 2002; 59: 233-9 (Pubitemid 34212500)
48. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depressionseverity and antidepressant medications. J Affect Disord 1998; 48: 25-36 (Pubitemid 28078968)
49. Igaku Tushinsya. Quick reference to tariff for health care services. Tokyo: Igaku Tushinsya, 2005
50. NHS Prescription Services [online]. Available from URL: http://www.nhsbsa.nhs.uk/prescriptions [Accessed 2012 Feb 20]
51. BritishMedical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. 45th ed. London:BMJ Publishing Group and Pharmaceutical Press, 2003
52. Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptakeinhibitor use. J Manag Care Pharm 2001; 7: 402-6
53. Drugstore.com, inc. Drugstore.com [online]. Available from URL: http://www.drugstore.com [Accessed 2011 Jan 27]
54. Department of Health and Human Services, Health Care Financing Administration. Medicare program: revisions to payment policies under the physician fee schedule for calendar year 2003. Fed Regist 2003; 68: 9567
55. Baker CB, Woods SW. Cost of treatment failure for major depression: direct costs of continued treatment. AdmPolicy Ment Health 2001; 28: 263-77 (Pubitemid 32830283)
56. Burke WJ, Gergel I, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-6
57. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996; 11: 129-36 (Pubitemid 26194512)
58. Bougerol T, Scotto JC, Patris M, et al. Citalopram and fluoxetine in major depression: comparison of two clinicaltrials in a psychiatrist setting and in general practice. Clin Drug Investig 1997; 14 (2): 77-89 (Pubitemid 27367893)
59. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40mg citalopram, and placeboin the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181-8 (Pubitemid 23294925)
60. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo controlled 6 month study. Int Clin Psychopharmacol 1995; 10: 29-35
61. Thornicroft G, Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of theWHO collaborative study on the assessment of depressive disorders. Psychol Med 1993; 23: 1023-32 (Pubitemid 23358462)
62. Angst J, Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients: results of aprospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr 1995; 146: 17-23
63. Kela. Statistical yearbook of the Social Insurance Institution, Finland 2000. Helsinki: Kela, 2001
64. Runeson B, Wasserman D. Management of suicide attempters: what are the routines and the costs? Acta Psychiatrica Scandinavica 1994; 90: 222-8 (Pubitemid 24291623)
65. Lave JR, Frank RG, Schulberg HC, et al. Costeffectiveness of treatments for depression in primary carepractice. Arch Gen Psychiatry 1998; 55: 645-51 (Pubitemid 28340354)
66. British Medical Association and the Royal Pharmaceutical Society. British national formulary. 51st ed. London:BMJ Group and the Royal Pharmaceutical Society of Great Britain, 2006
67. Department of Health. NHS reference costs 2005-06 [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicy AndGuidance/DH-062884 [Accessed 2010 Jun 28]
68. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotoninreuptake inhibitors. Br J Psychiatry 2001; 178: 234-41 (Pubitemid 32183606)
69. PDR. Drug topics: red book (March 2002). Montvale (NJ): Medical Economics, 2002
70. - 2002 physicians fee and coding book: a comprehensive fee and coding reference. 13th ed. Augusta (GA): Health CareConsultants of America, 2001
71. Ventura D, Armstrong EP, Skrepnek GH, et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opinion 2007; 23: 245-50 (Pubitemid 46333371)
72. McLaughlin TP, Eaddy MT,Grudzinski AN.Aclaims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depressionrelated treatment charges. Clin Ther 2004; 26: 115-24 (Pubitemid 38241529)
73. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38 (Pubitemid 24013155)
74. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27: 672-6 (Pubitemid 351339455)
75. Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand 1997; 391: 22-30 (Pubitemid 27333215)
76. Cegedim Strategic Data. Cegedim strategic data - medical research. London: Cegedim Strategic Data, 2005
77. Perahia D, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008; 42: 22-34 (Pubitemid 47570043)
78. Center for Medicare and Medicaid Services. Physician fee schedule [online]. Available from URL: https://www.cms.gov/PhysicianFeeSched/ [Accessed 2005 Jan 3]
79. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the NationalComorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-105 (Pubitemid 37432885)
80. Simon GE, Von KorffM, Rutter C, et al. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ 2000; 320: 550-4 (Pubitemid 30175801)
81. Agency for Health Care Policy and Research, US Department of Health and Human Services. Depression in primarycare: treatment of major depression [clinical practice guideline no. 5]. Rockville (MD): AHCPR, 1993
82. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression:a prospective study. Am J Psychiatry 1992; 149: 795-800
83. Katon W, Rutter C, Ludman E, et al. A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 2001; 58: 241-7 (Pubitemid 32209678)
84. Moscicki EK. Epidemiology of suicide. In: Jacobs DG, editor. The Harvard Medical School guide to suicide assessment and intervention. San Francisco (CA): Josey- Bass, 1999: 40-51
85. Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primarycare. Pharmacoeconomics 1995; 8 (6): 524-40
86. Bennett KJ, Torrance GW, Boyle MH, et al. Development and testing of a utility measure for major, unipolar depression. Qual Life Res 2000; 9: 109-20 (Pubitemid 30670654)
87. Ackerman DL, Unutzer J, Greenland S, et al. Inpatient treatment of depression and associated hospital charges. Pharmacoepidemiol Drug Saf 2002; 11: 219-27 (Pubitemid 34537528)
88. Fallick BC, Fleischman CA. The importance of employerto- employer flows in the U.S. labor market. Washington, DC: Board of Governors of the Federal Reserve System, 2001
89. McDonald WM, Phillips VL, Figiel GS, et al. Costeffective maintenance treatment of resistant geriatric depression.Psychiatr Ann 1998; 28: 47-52
90. Tew JD, Mulsant BH, Haskett RF, et al. Acute efficacy of ECT in the treatment of major depression in the old-old.Am J Psychiatry 1999; 156 (12): 1865-70
91. Kamlet MS, Paul N, Greenhouse J, et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995; 16: 17-40
92. Lcbowit BL, Manme RA, Niederehe G, et al. NIMH/ MacArthur Poundalion workshop report. PsychophannacolBull 1995; 31: 185-202
93. Hatziandreu FJ, Brown RE, Recvicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994; 5 (3): 249-68
94. Sackett DL, Torrence GW. The utility of different health states as perceived by the general public. J Chron Dis1978; 31: 697-704
95. Keller M, Yan B, Dunner D, et al. Recurrence prevention: efficacy of two years of maintenance treatment with venlafaxine XR in patients with recurrent unipolar major depression. 159th Annual Meeting of the American PsychiatricAssociation; 2006 May 20-25; Toronto (ON)
96. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressivedisorders: a systematic review. Lancet 2003; 361: 653-61 (Pubitemid 36246547)
97. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997; 170: 205-28 (Pubitemid 27117683)
98. Sobocki P, Ekman M, Agren H, et al. Health-related quality-of-life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007; 10: 153-60 (Pubitemid 46481142)
99. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 621-35 (Pubitemid 34056332)
100. Sobocki P, Ekman M, Agren H, et al. Resource-use and costs associated with patients treated for depression inprimary care. Eur J Health Econ 2007; 8: 67-76 (Pubitemid 46295341)
101. Drummond M, McGuire A. Economic evaluation in health care. New York (NY): Oxford University Press, 2006
102. Parikh SV, Lam RW, CANMAT Depression Work Group. Clinical guidelines for the treatment of depressivedisorders I: definitions, prevalence, and health burden. Can J Psychiatry 2001 Suppl. 1; 46: 13S-20S
103. Drummond MF, Sculpher MJ, Torrance GW. Methods for the economic evaluation of health care programmes. NewYork (NY): Oxford University Press, 2006
104. Klein RW, Dittus RS, Roberts SD, et al. Simulation modelling and health care decision making. Med Decis Making 1993; 13: 347-54
105. Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and predicators of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010; 122: 184-91
106. Lewinsohn PM, Rohde P, Seeley JR, et al. Natural course of adolescent major depressive disorder in community sample: predicators of recurrence in young adults. Am J Psychiatry 2000; 157 (10): 1584-91
107. Conradi HJ, Jonge P, Ormel J. Prediction of the three-year course of recurrent depression in primary care patients:different risk factors for different outcomes. J Affect Disord 2008; 105: 267-71 (Pubitemid 350236352)
108. Kessing LA, Andersen PK. The effect of episodes on recurrence in affective disorder: a case register study. J AffectDisord 1999; 53: 225-31 (Pubitemid 29287660)
109. Schulberg HC, Katon W, Simon GE, et al. Treating major depression in primary care practice: an update of theAgency for Healthcare Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55: 1121-7 (Pubitemid 28558285)
110. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder.3rd ed. [online]. Available from URL: http://www.psych.org/guidelines/mdd2010 [Accessed 2010 Oct 23]
111. National Collaborating Centre for Mental Health. Depression: the treatment and management of depression inadults [national clinical practice guideline no. 90]. London: British Psychological Society and Royal College of Psychiatrists, 2010
112. Le Lay A, Despiegel N, Francois C, et al. Can discrete event simulation be of use in modelling major depression?Cost Eff Resour Alloc 2006; 4: 19
113. Karnon J. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ 2003; 12: 837-48 (Pubitemid 37220634)
114. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23 (4): 323-32 (Pubitemid 40677051)
115. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60 Suppl. 22: 29-34 (Pubitemid 30107953)
116. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry1999; 60 Suppl. 22: 7-11
117. Steffens DC, McQuoid DR, Krishnan KRR. Partial response as a predictor of outcome in geriatric depression.Am J Geriatr Psychiatry 2003; 11: 340-8 (Pubitemid 36523302)
118. Sartorius N. One of the last obstacles to better mental health care: the stigma of mental illness. Neuropsychiatr 2002; 16: 5-10 (Pubitemid 35033631)
119. Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000; 17 (5): 445-59 (Pubitemid 30398804)
120. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatientswith major depression. Ann Clin Psychiatry 1997; 9: 157-64 (Pubitemid 27470387)
121. Nuijten MC. The selection of data sources for use in modeling studies. Pharmacoeconomics 1998; 13 (3): 305-16
122. Haji Ali Afzali H, Karnon J, Gray J. A proposed model for economic evaluations of major depressive disorder. Eur J Health Econ. Epub 2011 Jun 2